Detection Technology (DETEC) Q4 2025 earnings summary

Executive summary

• Q4 net sales were EUR 29.7 million, down 6.1% year-over-year, mainly due to currency headwinds; full-year net sales reached EUR 101.0 million, a 6.0% decrease.

• Medical segment showed strong growth (+19% in Q4, +10.6% for the year), driven by CT and healthcare reform in China; security (-29% Q4, -22.8% year) and industrial (-7% Q4, -2.2% year) declined.

• APAC region accounted for about 70% of sales, with EMEIA and Americas declining due to weak security performance.

• The company launched its DT2030 strategy, focusing on value-added, data-generating X-ray detector solutions and expanded its product portfolio.

• Major achievements included being named GE HealthCare's Supplier of the Year and commissioning a new factory in India.

Financial highlights

• Q4 EBITDA/EBITA was EUR 3.7 million (12.4% margin), down from EUR 5.2 million (16.3%) year-over-year; full-year EBITDA/EBITA was EUR 9.6 million (9.5% margin).

• Earnings per share for Q4 were EUR 0.22 and for the year EUR 0.44, both down from the previous year.

• Cash flow from operations for the year was EUR 3.9 million, significantly lower than EUR 20.1 million in the prior year.

• R&D expenses were fully expensed, totaling EUR 11.3 million for the year (11.2% of sales).

• Dividend proposal of EUR 0.30 per share, representing a 68% payout ratio.

Outlook and guidance

• Double-digit net sales growth is expected in Q1 and H1 of the coming year, with all segments and regions projected to grow despite ongoing FX and geopolitical headwinds.

• Medium-term targets include annual sales growth above 10% and an EBITDA/EBITA margin of 15%.

• Financial targets remain: at least 10% annual growth, at least 15% EBITDA margin, and dividend payout of 30-60% of net profit.

• Pricing is expected to remain relatively flat; volume growth is the main driver for the outlook.

• Geopolitical risks, tariffs, material shortages, and price competition, especially in China, create uncertainty.